Cancer of Prostate Clinical Trial
Official title:
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.
This study explores the use of local consolidation therapy in the setting of Darolutamide in the initial diagnosis of metastatic castrate resistant prostate cancer (mCRPC). In the chemotherapy naïve mCRPC setting, the pattern of disease is of limited volume metastases (1-5) in 34%-40% of cases. As progression at known sites of macroscopic disease is the predominant cause of failure on systemic therapies, local consolidation therapy with stereotactic ablative body radiotherapy (SABR) may improve progression free survival (PFS) and overall survival (OS). This approach has been tested in the setting of lung cancer, in which consolidation SABR has resulted in OS benefit (HR of 0.40) in phase II studies. The novel approach of local consolidation therapy has not been tested as yet in mCRPC. The secondary objective of this study proposal is to better understand the pattern of disease distribution at first diagnosis of CRPC. Previous studies have used conventional bone scan and CT imaging, and with these investigations the proportion of patients that are 'M0' is ~35%1. However, in the new era of PSMA PET, which is far more sensitive than conventional imaging, there exists a new group of men who are M0 on conventional imaging but are M1 on PSMA PET staging. Thus, in the DECREASE study population, we expect the vast majority of patients with conventionally imaged 'M0 CRPC' will have disease detectable on PSMA PET scanning. In this context, the central hypothesis of this trial is that the addition of consolidation radiotherapy to darolutamide to PSMA detected sites of disease will improve the clinical outcome of patients compared to those patients receiving darolutamide alone. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03031418 -
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
|
||
| Completed |
NCT01639859 -
Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci
|
N/A | |
| Not yet recruiting |
NCT06406803 -
The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients
|
N/A | |
| Completed |
NCT02362464 -
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
|
Phase 2 | |
| Enrolling by invitation |
NCT05844761 -
Real-time Motion Management During Prostate and Lung Radiotherapy
|
N/A | |
| Completed |
NCT03442075 -
Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy
|
||
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Completed |
NCT03444532 -
Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia
|
N/A | |
| Recruiting |
NCT05600400 -
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
|
N/A | |
| Recruiting |
NCT04887935 -
Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02235142 -
Prostatic Cancer Versus Androgen Deficiency
|
N/A | |
| Recruiting |
NCT06318559 -
Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention
|
N/A | |
| Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 | |
| Active, not recruiting |
NCT03632980 -
Dynamic Focusing Evaluation for Prostate Cancer Treatment
|
N/A | |
| Recruiting |
NCT04258813 -
Onco-primary Care Networking to Support TEAM-based Care
|
N/A | |
| Recruiting |
NCT05361798 -
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
|
Phase 2 | |
| Completed |
NCT04304196 -
Tailored, wEb-based, Psychosocial and Physical Activity Self-Management PrOgramme
|
N/A |